SC
SCPX.US Scorpius Holdings Inc
- Market cap
- USD 12.2K
- P/E
- -
- P/B
- 0.11x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Dec 2025.
Is SCPX.US undervalued?
Graham numberThe Graham number of Scorpius Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Scorpius Holdings Inc fundamental analysis
No fundamental analysis for Scorpius Holdings Inc yet.
Scorpius Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Scorpius Holdings Inc
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell…
Full company profileScorpius Holdings Inc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 4 quarters up to Dec 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Scorpius Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 342K | 1.52M | 5.79M | 3.05M | 2.95M | 2.11M | 5.98M | 6.99M | 6.24M | 1.72M |
| Gross Profit | -116K | 342K | 1.52M | 5.79M | 3.05M | 2.95M | 1.42M | -420K | -2.22M | 3.05M | -936K |
| Operating Income | -21.0M | -13.1M | -13.1M | -17.5M | -19.4M | -26.1M | -35.4M | -45.7M | -42.0M | -33.6M | -33.2M |
| EBITDA | -20.9M | -12.3M | -13.0M | -17.2M | -19.2M | -24.6M | -34.9M | -38.3M | -34.0M | -26.2M | -20.2M |
| Net Income | -20.3M | -12.6M | -11.8M | -15.7M | -20.0M | -26.0M | -35.1M | -43.4M | -45.2M | -32.8M | -22.1M |
| EPS | -699,828 | -199,587 | -86,436 | -25,215 | -16,836 | -326 | -282 | -339 | -347 | -13 | -0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 13.2M | 8.90M | 20.2M | 37.8M | 53.8M | 124M | 121M | 104M | 51.0M | 39.2M | 20.8M |
| Total Liabilities | 10.7M | 2.06M | 14.4M | 7.52M | 40.7M | 8.70M | 8.93M | 32.0M | 22.7M | 37.5M | 27.7M |
| Shareholders' Equity | 2.50M | 6.84M | 5.78M | 30.2M | 13.2M | 115M | 112M | 72.4M | 28.3M | 6.30M | -1.33T |
| Cash & Short-term Investments | 11.6M | 7.84M | 9.76M | 27.7M | 14.8M | 112M | 96.4M | 44.3M | 2.39M | 2.38M | 601K |
| Total Debt | 6.75M | - | - | - | 1.93M | 1.85M | 1.93M | 9.39M | 14.0M | 28.5M | 18.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -17.4M | -13.5M | -6.30M | -21.4M | -12.8M | -22.0M | -38.1M | -5.70M | -31.5M | -26.0M | -40.8M |
| Capital Expenditure | 116K | 45.9K | 61.4K | 594K | 265K | 338K | 1.90M | 20.1M | 1.99M | 875K | 237K |
| Free Cash Flow | -17.6M | -13.6M | -6.37M | -22.0M | -13.1M | -22.4M | -40.0M | -25.8M | -33.5M | -26.9M | -41.0M |
| Ratios | |||||||||||
| ROE | -813.4% | -183.8% | -204.8% | -52.0% | -152.1% | -22.6% | -31.3% | -60.0% | -159.8% | -520.8% | - |
| ROA | -153.5% | -141.3% | -58.7% | -41.7% | -37.2% | -21.0% | -29.0% | -41.6% | -88.6% | -83.7% | -106.3% |
| Net Profit Margin | - | -3,680.4% | -779.1% | -271.6% | -656.5% | -883.7% | -1,659.9% | -726.2% | -646.4% | -525.5% | -1,285.0% |
| Debt to Equity | 2.70x | - | - | - | 0.15x | 0.02x | 0.02x | 0.13x | 0.50x | 4.53x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Scorpius Holdings Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 97.1K | 1.21 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:200 on Jul 18, 2024.
Who owns Scorpius Holdings Inc
- Insiders 0.03%
- Institutions 0.00%
- Public & others 99.97%
- Shares outstanding 61.1M
- Free float 61.1M
Scorpius Holdings Inc company profile
- Company name
- Scorpius Holdings Inc
- Ticker
- SCPX.US
- Exchange
- USA Stocks
- Listed since
- Jul 24, 2013
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 90
- Fiscal year end
- December
- Address
- 1305 East Houston Street, San Antonio, TX, United States, 78205
- Phone
- 919 240 7133
- Website
- scorpiusbiologics.com
About Scorpius Holdings Inc
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services. The company serves the biotechnology and biopharmaceutical industries. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in San Antonio, Texas.
Scorpius Holdings Inc management
5- Mr. Jeffrey Alan Wolf J.D.Founder, Chairman, President & CEO · born 1963
- Dr. Justin Stebbing FRCP, FRCPath, M.A., M.D., Ph.D.Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
- Colonel George E. Peoples Jr., F.A.C.S., M.D.Chief Medical Advisor · born 1963
- Mr. Joe PaynePresident & COO of Scorpius BioManufacturing
- Ms. Nicole TempleSenior Manager & Head of Program Management